Bristol-Myers Squibb (B-MS) has outsourced the manufacture of some of its products to Sigma Pharmaceuticals, an Australia-based company that also bought a facility from the big pharma for A$60m ($51.7m).
New Sanofi Aventis chief Christopher Viebacher has virtually ruled out major acquisitions, eschewing the trend started by Pfizer’s $68bn (€53bn) swoop for Wyeth in favour of an anti-mega merger stance like that adopted by UK rival GSK.
Switzerland-based Schweizerhall appears to have circumnavigated
patent law, with approval of its generic version of Bristol-Myers
Squibb's (BSM) and Sanofi-Aventis' Plavix (clopidogrel bisulfate)
in Germany "expected...
A report to be published next week predicts that US and EU pharmas
will lose up to $100bn in revenues over the next five years as
generic products take advantage of major branded products losing
French pharmaceutical company, Sanofi-Aventis, reported an increase
in sales for the fourth quarter with its vaccine business
continuing to impress. The company's performance precedes two
upcoming decisions later this year that...
The growth in the global pharmaceutical continued to slow in 2004,
with a 7 per cent hike to $550 billion, as the sector felt the
effects of increased pricing pressure and the expanding market for
lower-cost generic drugs, reports...